Patient with Type 2 diabetes, proliferative diabetic retinopathy, traction retinal detachment, and age-related cataracts ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of blindness ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Ocular Therapeutix, Inc.’s OCUL share price has surged by 6.02%, which has investors questioning if this is right time to ...

EyePoint Pharmaceuticals, Inc.’s EYPT share price has surged by 6.87%, which has investors questioning if this is right time ...

Patients with diabetes may not need to have a HbA1c value lower than 8% before cataract surgery to reduce the risk for endophthalmitis.